IPP Bureau
Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
By IPP Bureau - January 12, 2026
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
By IPP Bureau - January 12, 2026
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
PharmaForceIQ acquires Aktana, launches first “optichannel-in-a-box” platform for pharma
By IPP Bureau - January 12, 2026
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
FDA rejects Vanda’s jet lag drug in current form
By IPP Bureau - January 12, 2026
Vanda strongly disputes the FDA’s reasoning
Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
By IPP Bureau - January 12, 2026
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe
By IPP Bureau - January 12, 2026
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
NAMSA expands US footprint with Labcorp medical device testing acquisition
By IPP Bureau - January 12, 2026
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
Alembic announces USFDA tentative approval for Bosutinib tablets
By IPP Bureau - January 12, 2026
Diabeloop bags FDA nod for DBLG2, opens US market for automated insulin delivery
By IPP Bureau - January 12, 2026
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies
By IPP Bureau - January 12, 2026
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility
By IPP Bureau - January 12, 2026
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility
By IPP Bureau - January 12, 2026
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Novartis to open Florida radioligand facility
By IPP Bureau - January 12, 2026
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
By IPP Bureau - January 11, 2026
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
By IPP Bureau - January 11, 2026
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
